CG Oncology (CGON) Set to Release Earnings on Friday

Key Points

• CG Oncology is expected to report Q3 2026 results before market open Friday, November 13. Analysts forecast a loss of $0.83 per share and revenue of $0.55 million.
• In its previous quarter, the company reported a $0.90-per-share loss, worse than the $0.66 loss analysts expected, while revenue of $1.16 million topped estimates of $0.36 million.
• Analyst sentiment is broadly positive: CG Oncology has a “Moderate Buy” consensus rating and an average price target of $87.50, though some firms maintain sell ratings.

CG Oncology (NASDAQ:CGON - Get Free Report) will likely be announcing its Q3 2026 results before the market opens on Friday, November 13th. Analysts expect the company to post earnings of ($0.8341) per share and revenue of $0.55 million for the quarter. Parties may review the information on the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 12, 2026 at 12:30 PM ET.

CG Oncology (NASDAQ:CGON - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.90) EPS for the quarter, missing analysts' consensus estimates of ($0.66) by ($0.24). CG Oncology had a negative net margin of 3,602.68% and a negative return on equity of 25.20%. The business had revenue of $1.16 million during the quarter, compared to analyst estimates of $0.36 million. On average, analysts expect CG Oncology to post ($3.31) EPS for the current fiscal year and ($3.12) EPS for the next fiscal year.

CG Oncology Stock Performance

Shares of NASDAQ:CGON opened at $64.80 on Friday. The company has a 50-day simple moving average of $68.29 and a 200-day simple moving average of $65.99. CG Oncology has a one year low of $35.80 and a one year high of $80.97. The stock has a market capitalization of $5.74 billion, a price-to-earnings ratio of -24.09 and a beta of 0.35.

Insiders Place Their Bets

In related news, Director Leonard E. Post sold 1,000 shares of CG Oncology stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $62.06, for a total value of $62,060.00. Following the transaction, the director directly owned 1,000 shares in the company, valued at $62,060. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In the last 90 days, insiders have sold 3,000 shares of company stock valued at $209,580. Company insiders own 4.80% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on CGON. Truist Financial raised their price target on CG Oncology from $82.00 to $85.00 and gave the stock a "buy" rating in a report on Friday, August 7th. Piper Sandler boosted their price target on CG Oncology from $82.00 to $85.00 and gave the company an "overweight" rating in a research report on Friday, August 7th. Royal Bank Of Canada reduced their price objective on CG Oncology from $81.00 to $79.00 and set an "outperform" rating for the company in a research note on Friday, August 7th. Wall Street Zen cut CG Oncology from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 8th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of CG Oncology in a research report on Thursday, October 15th. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $87.50.

About CG Oncology

CG Oncology, Inc NASDAQ: CGON is a clinical-stage biotechnology company focused on developing therapies for bladder cancer and other cancers affecting the urinary tract. The company is developing medicines designed to stimulate the immune system and target tumor cells within the bladder.

Its lead product candidate is cretostimogene grenadenorep, an investigational intravesical therapy based on an oncolytic adenovirus. The treatment is designed to be administered directly into the bladder, where it may selectively infect cancer cells, promote their destruction and activate an immune response against the tumor.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.